PRVA Stock Overview
Privia Health Group, Inc. operates as a national physician-enablement company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Privia Health Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.17 |
| 52 Week High | US$30.15 |
| 52 Week Low | US$17.54 |
| Beta | 0.81 |
| 1 Month Change | -4.82% |
| 3 Month Change | -20.06% |
| 1 Year Change | -30.75% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.71% |
Recent News & Updates
Recent updates
Analysts Just Slashed Their Privia Health Group, Inc. (NASDAQ:PRVA) EPS Numbers
Mar 03
The Price Is Right For Privia Health Group, Inc. (NASDAQ:PRVA)
Feb 27There Are Reasons To Feel Uneasy About Privia Health Group's (NASDAQ:PRVA) Returns On Capital
Jan 31Why Privia Health Group, Inc. (NASDAQ:PRVA) Could Be Worth Watching
Dec 03Privia Health Group, Inc.'s (NASDAQ:PRVA) Price In Tune With Revenues
Nov 06Privia Health Group's (NASDAQ:PRVA) Returns On Capital Not Reflecting Well On The Business
Aug 08Privia Health Group, Inc. (NASDAQ:PRVA) Shares Could Be 48% Below Their Intrinsic Value Estimate
Mar 17Privia Health: In Line For Solid FY22, Hold On Valuation
Sep 15Privia Health Group reports Q2 earnings beat; raises FY22 outlook
Aug 11Privia Health Group Grows But Operating Results Await
Jun 20Is Privia Health Group, Inc. (NASDAQ:PRVA) Trading At A 48% Discount?
Feb 09Privia Health Group: Not Healthy Yet
Feb 06A Look At The Fair Value Of Privia Health Group, Inc. (NASDAQ:PRVA)
Nov 11Calculating The Intrinsic Value Of Privia Health Group, Inc. (NASDAQ:PRVA)
Jul 29Privia Health Group, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 28Disrupting Healthcare - IPO Interview With Privia Health CEO Shawn Morris (Video)
May 03Privia Health Group: Good Intentions Do Not Automatically Make A Good Investment
May 01Shareholder Returns
| PRVA | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 1.8% | 2.0% | 1.2% |
| 1Y | -30.8% | 3.4% | 24.9% |
Return vs Industry: PRVA underperformed the US Healthcare industry which returned 3.6% over the past year.
Return vs Market: PRVA underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| PRVA volatility | |
|---|---|
| PRVA Average Weekly Movement | 6.9% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRVA's share price has been volatile over the past 3 months.
Volatility Over Time: PRVA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,102 | Parth Mehrotra | www.priviahealth.com |
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers’ workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts.
Privia Health Group, Inc. Fundamentals Summary
| PRVA fundamental statistics | |
|---|---|
| Market cap | US$2.23b |
| Earnings (TTM) | US$23.08m |
| Revenue (TTM) | US$1.66b |
93.4x
P/E Ratio1.3x
P/S RatioIs PRVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRVA income statement (TTM) | |
|---|---|
| Revenue | US$1.66b |
| Cost of Revenue | US$1.50b |
| Gross Profit | US$161.50m |
| Other Expenses | US$138.42m |
| Earnings | US$23.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 0.19 |
| Gross Margin | 9.74% |
| Net Profit Margin | 1.39% |
| Debt/Equity Ratio | 0% |
How did PRVA perform over the long term?
See historical performance and comparison